NCT06301971View on ClinicalTrials.gov

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

April 4, 2024

Study Completion Date

April 4, 2024

Conditions
Healthy Participants
Interventions
DRUG

Emraclidine

Oral solution/suspension

Trial Locations (1)

78744

Austin, Texas, Austin

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT06301971 - A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants | Biotech Hunter | Biotech Hunter